Adimab Provides Mid-Year Update on 2017 Partnership Activity

09:00 EDT 21 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
- 10 New Partnerships - - Over 20 Milestones Achieved - - 6 New Commercial Licenses - Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibod...

Other Sources for this Article

Adimab, LLC.
Guy Van Meter, 603-653-5775
VP of Business Development


More From BioPortfolio on "Adimab Provides Mid-Year Update on 2017 Partnership Activity"

Quick Search


Relevant Topics

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...